



SUNESIS

Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference

March 13, 2018

Cancellation due to Travel Changes Caused by Inclement Weather

Management to Proceed with Scheduled Investor Meetings via Conference Calls

SOUTH SAN FRANCISCO, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the cancellation of the company's presentation and webcast at the Cowen & Company 38th Annual Health Care Conference, previously scheduled to take place today, March 13th, at 8:00 AM Eastern Time at the Marriott Copley Place in Boston.

Management is no longer able to attend the conference as planned due to inclement weather in Boston. Willie Quinn, Chief Financial Officer, and Dayton Misfeldt, Interim Chief Executive Officer, will hold all scheduled investor meetings as phone calls. If you are an institutional investor with a scheduled meeting with Sunesis management, please proceed to your meeting room at the conference as planned, and reach out to maeve@argotpartners.com with any questions.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in clinical trials for solid tumors, and Sunesis' proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.

For additional information on Sunesis, please visit www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Investor and

Media

Inquiries:

Maeve

Conneighton

Willie Quinn

Sunesis

Argot

Partners

Pharmaceuticals

Inc.

212-600-1902

650-266-3716

 [Primary Logo](#)

Source: Sunesis Pharmaceuticals, Inc.